The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Abstract Mutation in KRAS protooncogene represents one of the most common genetic alterations in NSCLC and has posed a great therapeutic challenge over the past ~ 40 years since its discovery. However, the pioneer work from Shokat’s lab in 2013 has led to a recent wave of direct KRASG12C inhibitors...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-11-01
|
| Series: | Experimental Hematology & Oncology |
| Online Access: | https://doi.org/10.1186/s40164-023-00453-8 |